Abstract
REPORT HIGHLIGHTS
The global market for advanced drug delivery systems amounted to $134.3
billion in 2008, and was projected to increase to $139 billion in 2009. The
estimate for 2014 is $196.4 billion, for a compound annual growth rate (CAGR)
of 7.2% in the 5-year period. The largest segment of the market is targeted
drug delivery, which reached $50.9 billion in 2009 and is expected to increase
to $80.2 billion in 2014, for a CAGR of 9.5%. Sustained-release products have
the second-largest market share, with estimated sales of $36.1 billion in 2009
and $45.8 billion in 2014, for a CAGR of 4.9%.
INTRODUCTION
STUDY OBJECTIVES
BCC' s goal in conducting this study is to provide an overview of the current
and potential aspects of the global market for advanced drug delivery systems
and its future direction, with an emphasis on newer techniques and products.
The report determines the market size and market leaders, provides a market
overview, and examines factors affecting the markets for drug delivery
systems, including the use of these products in therapeutic markets.
An overview of types of drug delivery systems is also examined along with
sales figures over the 5 year period from 2009 to 2014. This study provides
an overview of the drug delivery market, which BCC projects will grow at a
compound annual growth rate (CAGR) of 7.2% over the forecast period 2009
through 2014.
The study presents market size and future trends, profiles market leaders, and
analyzes factors affecting drug delivery markets and important products. The
report also examines future trends in drug delivery technology, the basic
principles underlying different systems, and their applications. Companies
manufacturing and selling the drug delivery products are also profiled.
Revenues have been broken down by the type of drug delivery systems and by
different regions.
Our key objective is to present a comprehensive analysis of the current market
and the future direction of the advanced drug delivery systems.
REASONS FOR DOING THIS STUDY
The drug delivery market is changing drastically due to the introduction of
new techniques and routes of delivery. R&D spending, along with increasing
competition, patent expiries, new technologies, an international marketplace,
and a changing customer base, is creating a new kind of market for drug
delivery systems. This study looks at almost all the systems affected by
these factors.
This is a very complex market, where many technologies are combined together
to produce a better delivery system, thus creating niche markets with very
specialized applications. The use of liposomes, polymers, etc. in the
sustained-release oral/injectable drug delivery market is a good example.
Prodrugs, PEGylation, nanoparticles, and liposomes are significant new markets.
Acquisition strategies and collaborations by companies are also covered in
this report, for example, the acquisition of the Pulmonary Division of Nektar
Therapeutics by Novartis. This study also discusses the strength and
weaknesses of drug development market in light of the new technologies,
growing competition, and changing customer needs.
INTENDED AUDIENCE
The report consolidates much of the information on new products and new
technologies in the drug delivery industry. The study contributes to
understanding market growth and decline in drug delivery market from the point
of view of the manufacturer and user. This study will be of interest to
manufacturers and end-users in the pharmaceutical and biotechnology
industries, and to companies involved in R&D for drug delivery systems and new
drugs.
SCOPE OF THE STUDY
This study encompasses the major types of drug delivery systems used in the
health industry. BCC analyzes each technology and looks at the manufacturers,
their new products, sales estimates, market projections, and some market share
information. BCC analyzes the industry on a worldwide basis. Patents for drug
delivery technologies are also studied by year, country, and assignee. The
Food and Drug Administration (FDA) approvals for the past 5 years have been
covered. New developments in this field have been examined in detail,
including those that comprise a part of individual company profiles.
METHODOLOGY
Both primary and secondary research methods were used in this report. A
comprehensive search of the literature was conducted. The literature included
technical newsletters and journals as well as many other sources. The data
were collected through interviews and correspondence with various
pharmaceutical/ biotechnical experts. Projections were based on estimates such
as the current number of end users, potential end users, likely unit prices,
rates of consumption, and market trends.
INFORMATION SOURCES
BCC surveyed many companies to obtain data for this study. We gathered the
data from these industries, spoke with officials, and consulted newsletters,
company literature, product literature, a host of technical articles,
journals, indexes, and abstracts. Exhaustive investigations of databases by
key terminology were done. In addition, we compiled data from current
financial and trade information and government sources.
| 
View Cart
